Plasma exchange and treatment with Soliris (eculizumab) may be used successfully to treat pregnancy-related atypical hemolytic uremic syndrome (aHUS) complicated by kidney failure, a case report suggests. The report, “Atypical hemolytic uremic syndrome: when pregnancy leads to lifelong dialysis: a case report and literature review,” was published in…
News
A 57-year old man developed atypical hemolytic uremic syndrome (aHUS) after being bitten by a pit viper belonging to the Bothrops aspe species, a recent case report suggests. According to its authors, this is the first report describing an association between aHUS and this viper species, likely triggered by venom-induced…
Soliris (eculizumab), given as a treatment or as a preventive measure, reduces disease relapse and kidney transplant loss in people with atypical hemolytic uremic syndrome (aHUS), according to a Brazilian retrospective study. Researchers emphasized the need, in low- to medium-income countries, to provide greater access to Soliris and similar…
If closely monitored, women with atypical hemolytic uremic syndrome (aHUS) can have successful and uncomplicated pregnancies, including those on dialysis or patients who had undergone a kidney transplant, according to a new study. Additionally, researchers confirmed that patients can safely and effectively be treated with Soliris (eculizumab), an…
COVID-19 appears to have triggered an exaggerated immune response in a toddler, leading to the development of atypical hemolytic uremic syndrome (aHUS) in the absence of disease-relevant mutations, scientists reported. “This is a rare case report of a child with COVID-19 developing HUS. Since HUS developed following a COVID-19…
In their continued efforts to improve health equity for people with rare diseases, Global Genes and RARE-X have joined forces to help advocacy groups collect patient data and make the most of that information. “Patient data is perhaps the most valuable asset rare disease communities can leverage to…
The case of a woman with unusual symptoms for atypical hemolytic uremic syndrome (aHUS) — including normal hemoglobin levels and mildly low platelet counts — highlights the need for better and more clear diagnostic criteria for this condition, according to researchers. The goal is to ensure that patients can…
Global Genes has partnered with the Rare Disease Diversity Coalition (RDDC) to advance health equity for rare disease patients and caregivers in underrepresented communities of color. “For rare disease patients, there are many challenges — and for people of color with a rare disease, these challenges are compounded…
The Rare Disease Diversity Coalition (RDDC) awarded $600,000 in grants to ease the disparities faced by rare disease patients of color. These Impact Rare Disease Solution grants will go five RDDC steering committee working groups, which aim to identify problems for rare disease communities and advocate for solutions. The five…
Atypical hemolytic uremic syndrome (aHUS) can co-exist with severe combined immunodeficiency (SCID), a rare genetic disorder characterized by a weakened immune system, a case report noted. Prompt diagnosis is crucial to improving patient outcomes, its researchers wrote, especially as the two diseases “are considered to exacerbate each other.” The…
Recent Posts
- aHUS drug Soliris helps reverse organ failure in young woman in rare case
- A ‘glow-up’ is just the boost I’ve needed in life with rare diseases
- Unexpected gene therapy finding may help treat two rare kidney diseases
- How aHUS treatment led to my first tattoos
- Ultomiris at lower doses just as safe, effective for children with aHUS: Study
- Strange symptoms make me wonder if I’m having neurological complications
- Leaky artificial heart valve triggers rare aHUS in woman, 70: Report
- How my body naturally reacts to one of my bad habits
- Study finds alternative pathway is main driver of aHUS
- Rapid, sustained aHUS response seen with Ultomiris in real-world data